Skip to main content
. 2022 Jul 19;13(5):2436–2446. doi: 10.1002/jcsm.13052

Table 2.

Demographics and clinical outcomes based on survival in CT COVID cohort (n = 95)

Alive (n = 79) Dead (n = 16) P‐value 1
Clinical outcomes
Age (in years) (mean (SD)) 63.1 (13.7) 64.3 (17.4) 0.773
Sex (female) (%) 37 (46.8) 8 (50.0) 1
BMI 2 (mean (SD)) (kg/m2) 32.5 (9.26) 29.2 (6.39) 0.177
Race (African‐American) (%) 21 (26.6) 4 (25.0) 1
Hospital length of stay (in days) (median (IQR)) 13.0 (6.0, 28.0) 21.0 (13.8, 37.3) 0.028*
ICU admission (%) 39 (49.4) 13 (81.2) 0.039
Mechanical ventilation (%) 25 (69.4) 13 (92.9) 0.17
PM CSA (initial) (cm2) (median (IQR)) 33.1 (26.0, 47.0) 31.0 (27.2, 34.9) 0.383*
PM CSA (final) (cm2) (median (IQR)) 32.1 (24.1, 42.2) 27.6 (24.8, 29.1) 0.076*
Per cent change in PM CSA (cm2) (standardized to 30 days) (median (IQR)) −1.14 (−5.17,‐0.24) −2.69 (−8.81,‐1.54) 0.037
ESM CSA (initial) (cm2) (median (IQR)) 37.0 (30.8, 46.8) 27.8 (24.5, 37.3) 0.025*
ESM CSA (final) (cm2) (median (IQR)) 35.1 (27.2, 43.3) 27.10 (23.7, 31.4) 0.009*
Per cent change in ESM CSA (cm2) (standardized to 30 days) (mean (SD)) −0.81 (−4.62,‐0.10) −2.18 (−10.9,‐0.70) 0.089
Lab results (on admission) (mean (SD))
CRP 2 (mg/L) 4.60 (1.75, 12.1) 14.5 (2.80, 22.4) 0.052*
Procalcitonin (ng/mL) 0.17 (0.09, 0.33) 0.24 (0.13, 0.82) 0.154*
Lactate (mmol/L) 1.63 (0.77) 2.14 (3.01) 0.359
d‐dimer (ng/mL) 1050 (600, 2760) 3175 (1065, 5440) 0.044*
WBC 2 (103 cells/μL) 6.80 (5.12, 8.61) 7.19 (5.02, 10.2) 0.865*
Absolute lymphocyte count (cells/μL) 1.03 (1.18) 1.14 (1.16) 0.740
1

P‐values represent pairwise Student's two‐tailed t‐tests for normally distributed continuous variables and Wilcoxon–Mann–Whitney rank sum test for non‐normally distributed variables (denoted by *). Non‐normally distributed variables are presented as median with interquartile range. Difference from control, P < 0.05.

2

BMI = body mass index; WBC = white blood cells; CRP = C‐reactive protein.